A Phase 2 interventional study of Lithium Carbonate and Placebo in Major Depressive Disorder, Dysthymia and Depression Not Otherwise Specified, sponsored by Columbia Northwest Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-08-24.
Sponsored by Columbia Northwest Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,500 studies in Depressive Disorder, Major with a site in United States — 215 open to participants now, 259 under way, 27 of them phase 3. Depressive Disorder, Major · United States.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, this one is the 605th largest by enrollment of the 1,323 interventional ones that give a count, is one of 69 that started in 2010, is one of 271 in phase 2, and was the 393rd registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →215 of the 1,500 studies in Depressive Disorder, Major with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 22–60
Baylor College of Medicine · Sites in United States
Ages 18–64
Ohio State University · Sites in United States
Ages 21–65
Florida State University · Sites in United States
Ages 18–55 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,500 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 135 · Phase 2 325 · Phase 3 262 · Phase 4 189
First in 1979; this study’s year is marked. 69 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 80 is close to the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 70 across the 1,323 interventional studies, 100 across the 171 observational. Of the 1,156 that completed or were terminated, 584 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
484 of 1,500 have an industry lead sponsor. The 10 most frequent:
Columbia Northwest Pharmaceuticals is the lead sponsor of 2 studies on the registry; none are open to participants now.
Columbia Northwest Pharmaceuticals has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
99 of the studies in Depressive Disorder, Major with a site in United States that are under way reach primary completion within a year, 10 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06922110Phase 3Xenon Pharmaceuticals Inc.An Open-Label Study of Azetukalner in Major Depressive Disorder | 2027-01 |
| NCT04041479Phase 3Weill Medical College of Cornell UniversityBiomarker-guided rTMS for Treatment Resistant Depression | 2027-04 |
| NCT05850689Phase 3Intra-Cellular Therapies, Inc.Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | 2027-04-05 |
| NCT07076407Phase 3Xenon Pharmaceuticals Inc.A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | 2027-05 |
Add all 99 to your calendar (.ics) → With an account.
Among the 1,500 studies in Depressive Disorder, Major with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators hypothesize that patients receiving citalopram in combination with lithium will have a greater reduction in depressive symptoms than patients receiving citalopram in combination with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo · Drug: Citalopram
Drug: Lithium Carbonate · Drug: Citalopram
300 mg one time per day for 4 weeks
Take one time daily for 4 weeks
All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
Also known as: Celexa
Sheehan-Suicidality Tracking Scale (S-STS)
The S-STS is an 14 item clinician administered prospective rating scale that scores both treatment-emergent suicidal ideations and suicidal behaviors with scores ranging from 0-40 points. Patients scoring a 0 are experiencing no suicidal thoughts, ideations, or attempts, while a score of 40 indicates a fatal, completed suicide. Comparison was made between the citalopram with lithium and the citalopram with placebo treatment groups. Outcome measures are expressed as change scores from the baseline visit to week 4.
Time frame: 4 weeks; from Baseline to Week 4
Beck Hopelessness Scale (BHS)
The BHS measures the extent of negative attitudes about the future. It has particular utility as an indirect indicator of suicidal risk in depressed examinees or individuals who have made suicide attempts. Comparison between citalopram and lithium and citalopram and placebo groups in the BHS will be made from baseline to week 4
Time frame: 4 weeks
Beck Scale for Suicide Ideation (BSS)
The BSS is a 21-item slef-report instrument used to detect ans measure the severity of suicidal ideation in adults. It measures a broad spectrum of attitudes and behaviors for assessing patient suicide risk, as well as reveals specific suicidal characteristics which require greater scrutiny. Comparison between citalopram and lithium and citalopram and placebo groups in the BSS will be made from baseline to week 4
Time frame: 4 weeks
There were 93 patients screened to meet the enrollment target of 80 randomized subjects into this study. Subjects were recruited from two clinical research centers beginning in March 2010. One site was located in Bellevue, WA, and the other in San Diego, CA. The last patient was screened in December 2010.
| Milestone | Placebo (Sugar Pill) | Lithium |
|---|---|---|
| Started | 40 | 40 |
| Completed | 32 | 32 |
| Not completed | 8 | 8 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Out of window | 4 | 3 |
| Withdrew: Moved out of state | 1 | 2 |
The S-STS is an 14 item clinician administered prospective rating scale that scores both treatment-emergent suicidal ideations and suicidal behaviors with scores ranging from 0-40 points. Patients scoring a 0 are experiencing no suicidal thoughts, ideations, or attempts, while a score of 40 indicates a fatal, completed suicide. Comparison was made between the citalopram with lithium and the citalopram with placebo treatment groups. Outcome measures are expressed as change scores from the baseline visit to week 4.
| Scores on a Scale (S-STSS) | Placebo (Sugar Pill) | Lithium |
|---|---|---|
| Sheehan-Suicidality Tracking Scale (S-STS) | 4.8 ± 5.5 | 5.0 ± 5.1 |
The BHS measures the extent of negative attitudes about the future. It has particular utility as an indirect indicator of suicidal risk in depressed examinees or individuals who have made suicide attempts. Comparison between citalopram and lithium and citalopram and placebo groups in the BHS will be made from baseline to week 4
Results for this outcome have not been posted.
The BSS is a 21-item slef-report instrument used to detect ans measure the severity of suicidal ideation in adults. It measures a broad spectrum of attitudes and behaviors for assessing patient suicide risk, as well as reveals specific suicidal characteristics which require greater scrutiny. Comparison between citalopram and lithium and citalopram and placebo groups in the BSS will be made from baseline to week 4
Results for this outcome have not been posted.
Collected over Adverse event reporting began at the time the patient screened for the study and signed the informed consent document. AEs were collected at each study visit and follow up phone call and could be reported 30 days after last dose of study medication.. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Sugar Pill) | — | 1/40 (2.5%) | 18/40 (45%) |
| Lithium | — | 1/40 (2.5%) | 21/40 (52.5%) |
| Event | Placebo (Sugar Pill) | Lithium |
|---|---|---|
| DepressionPsychiatric disorders | 1/40 | 0/40 |
| PsoriasisSkin and subcutaneous tissue disorders | 0/40 | 1/40 |
| Event | Placebo (Sugar Pill) | Lithium |
|---|---|---|
| HeadachesNervous system disorders | 1/40 | 9/40 |
| SomnolenceNervous system disorders | 7/40 | 6/40 |
| NauseaGastrointestinal disorders | 5/40 | 4/40 |
| AnxiousnessPsychiatric disorders | 2/40 | 3/40 |
| DyspepsiaGastrointestinal disorders | 0/40 | 3/40 |
| Upper Respitory InfectionRespiratory, thoracic and mediastinal disorders | 3/40 | 0/40 |
| DizzinessNervous system disorders | 2/40 | 2/40 |
| VomitingGastrointestinal disorders | 1/40 | 2/40 |
| Decreased AppetiteNervous system disorders | 2/40 | 2/40 |
| RestlessnessNervous system disorders | 2/40 | 0/40 |
| Age, Categorical(Participants) | Placebo (Sugar Pill) | Lithium | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 39 | 39 | 78 |
| >=65 years | 1 | 1 | 2 |
| Age Continuous(years) | Placebo (Sugar Pill) | Lithium | Total |
|---|---|---|---|
| Mean | 38.5 ± 15.2 | 45.0 ± 11.6 | 41.8 ± 13.8 |
| Sex: Female, Male(Participants) | Placebo (Sugar Pill) | Lithium | Total |
|---|---|---|---|
| Female | 25 | 19 | 44 |
| Male | 15 | 21 | 36 |
| Region of Enrollment(participants) | Placebo (Sugar Pill) | Lithium | Total |
|---|---|---|---|
| United States | 40 | 40 | 80 |
The record gives a start of Mar 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2011, 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lithium Carbonate
Columbia Northwest Pharmaceuticals